Antioxidant therapies

ApprovedSmall molecule

MMansoura University Hospital

Antioxidant therapies is one of 4 small molecule programs targeting Critical Illness. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Critical IllnessCompleted

Critical IllnessApproved

Completed

Competition

Competitive Landscape

4 competitors in Critical Illness

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Approved

1 2

Circadin

NNeurim Pharmaceuticals Ltd.

Approved

1 3

Lactoferrin

UUniversità degli Studi di Ferrara

Approved

1 4

Antioxidant therapies

MMansoura University Hospital

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Critical Illness1 trial

The Effect of Lactoferrin in Improving Clinical Outcomes in ICU Patients

Completed·MMansoura University Hospital·Approved·NCT05936528·660 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Antioxidant therapies. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antioxidant therapies compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antioxidant therapies. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mansoura University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMansoura University Hospital

Antioxidant therapies

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Critical Illness1 trial

References

Drug Info

Quick Facts

Related News